恆基地產(00012.HK)購買10.3萬股美麗華酒店(00071.HK)股份
格隆匯4月14日丨恆基地產(00012.HK)公吿,於2021年4月14日,公司透過其全資附屬公司間接在聯交所以每股美麗華股份平均價格(不包括交易成本)約港幣15.28元,總代價約港幣157.4萬元(不包括交易成本),購買合共10.3萬股美麗華酒店(00071.HK)股份,於本公佈日期,佔已發行美麗華股份總數約0.0149%。
該購買結算過程完成時,公司將間接持有合共3.45億股美麗華股份,佔已發行美麗華股份總數約50.002%。美麗華隨後將成為公司間接非全資附屬公司,而美麗華的財務業績將於集團的綜合財務報表內綜合入賬。公司於美麗華股份的權益乃作長期投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.